Results
weave.ly
Read more
i_iso and our services
Read more
Animab secures €10M for antibiotic-free animal health solution
Animab, a VUB-VIB-UGent spin-off, has secured €10 million in Series B funding to launch its innovative antibiotic-free solution for piglet health, tackling antimicrobial resistance.
Read more
Calling experts for Horizon Europe/Digital Europe and IPCC-workshops
We are looking for experts for two distinct initiatives within the realm of research and innovation. These calls present a unique opportunity to bolster the Brussels R&I ecosystem at both European and international levels. 1.
Read more
Swave Photonics raises €6M for holographic display technology
Swave Photonics, a spin-off from imec and VUB, has raised an additional €6 million in Series A funding. This follow-on investment will accelerate the development of Swave's innovative holographic display technology for Spatial + AI Computing.
Read more
Unified governance for data and AI
In a world awash with data, making sense of it and keeping it reliable can feel like navigating a stormy sea. From academic research to “unicorn” status, VUB spin-off Collibra redefined how organisations can trust, understand and use their data to create value.
Read more
How VUB spin-offs are reshaping fertility care
From non-invasive embryo selection to hormone-free IVF, VUB innovations are giving fertility care a human-centred upgrade — improving outcomes, access, and safety for people around the world.
Read more
Empowering amputees with a smart bionic foot
What if a prosthetic foot could move as naturally as a biological one? VUB spin-off Axiles Bionics is redefining mobility for lower limb amputees.
Read more
Bringing nature-based resilience to cities
With cities under increasing pressure from floods and heatwaves, BitaGreen transforms urban planning with nature-based solutions that not only protect against climate risks but also improve quality of life.
Read more
Precirix Receives FDA Green Light for Novel Cancer Therapy
VUB spin-off Precirix announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for CAM-FAP-Ac-225. This significant achievement paves the way for Precirix to begin a Phase 1 clinical trial for patients battling FAP-positive tumors.
Read more